The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.


Download and Print: Download Printer-friendly PDF Download data


Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2011-2015
Both Sexes by Race

Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Carcinoma 48,641 98.3% 38,647 98.3% 5,920 98.4% 3,656 98.1% 194 96.5% 5,268 97.9%
Epidermoid carcinomad (8051-8131) 145 0.3% 105 0.3% 22 0.4% 16 0.4% - - - -
Adenocarcinomae 42,038 84.9% 33,498 85.2% 5,105 84.8% 3,092 83.0% 171 85.1% 4,532 84.2%
Adenocarcinoma, NOS (8140) 33,949 68.6% 27,067 68.8% 4,218 70.1% 2,388 64.1% 142 70.6% 3,603 67.0%
Papillary adenocarcinoma, NOS (8260) 30 0.1% 25 0.1% - - - - - - - -
Mucinous adenocarcinoma (8480,8482) 1,114 2.3% 885 2.3% 103 1.7% 111 3.0% - - 136 2.5%
Mucin-producing adenocarcinoma (8481) 296 0.6% 238 0.6% 36 0.6% 21 0.6% - - 27 0.5%
Infiltrating duct carcinoma (8500-8503,8507,8514) 5,282 10.7% 4,192 10.7% 589 9.8% 468 12.6% 17 8.5% 564 10.5%
Other adenocarcinomaf 1,367 2.8% 1,091 2.8% 157 2.6% 101 2.7% - - 196 3.6%
Other specific carcinomasg 4,641 9.4% 3,651 9.3% 540 9.0% 391 10.5% 16 8.0% 508 9.4%
Islet cell carcinoma (8150-8155) 275 0.6% 228 0.6% 27 0.4% 16 0.4% - - 25 0.5%
Other carcinomash 4,366 8.8% 3,423 8.7% 513 8.5% 375 10.1% - - 483 9.0%
Unspecified, "Carcinoma, NOS" (8010,8020-8022) 1,818 3.7% 1,394 3.5% 253 4.2% 157 4.2% - - 216 4.0%
Sarcoma and other soft tissue tumorsi 40 0.1% 32 0.1% - - - - - - - -
Other specific typesj Unspecified (8000-8005) 53 0.1% 42 0.1% - - - - - - - -
764 1.5% 602 1.5% 90 1.5% 63 1.7% - - 94 1.7%
Total 49,499 100.0% 39,324 100.0% 6,019 100.0% 3,727 100.0% 201 100.0% 5,381 100.0%

Footnotes:

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551, 8560,8570-8574,8576,8940-8941.

g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575, 8580-8671.

h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

i Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373, 9540-9582.

j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.